Apr 24, 2019
Oncopeptides Provides New Guidance on the Patient Recruitment in the OCEAN Study and a Clinical Program Update in a Webcast at 10:00 (CET)
Apr 08, 2019
Actinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium
Mar 26, 2019
Janssen Submits Application for DARZALEX® (daratumumab) Combination Therapy to U.S. FDA for Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma
Feb 27, 2019
Data From Oncopeptides Clinical Trials HORIZON and ANCHOR Evaluating Melflufen in RRMM Selected for Presentation at the AACR Annual Meeting
Feb 12, 2019
U.S. FDA Approves DARZALEX® (daratumumab) Split-Dosing Regimen
Dec 04, 2018
New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma
Dec 03, 2018
Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma
Dec 02, 2018
Oncopeptides Presents First Interim Data From the Ongoing Combination Trial ANCHOR With Melflufen at the 60th American Society of Hematology Meeting
Dec 01, 2018
DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma
Nov 01, 2018
Oncopeptides to Present Updated Data From the Two Ongoing Trials ANCHOR and HORIZON in Patients with RRMM at ASH in December 2018
Oct 31, 2018
In Multiple Myeloma, Janssen's Darzalex Posted Significant Gains Over the Past Six Months, but May Face an Increasingly Restrictive Payer Environment
Sep 10, 2018
Medivir Appoints Dr. Linda Basse as Chief Medical Officer
Aug 20, 2018
Electrophysiology Devices Market Growth Intensifies on Heels of Latest Technological Advancements
Aug 08, 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing Regimen
Jun 07, 2018
Evolving Treatment Strategies in Multiple Myeloma: Janssen's Darzalex Leads a Host of Novel Agents in Redefining Treatment Strategies and Approaches
May 31, 2018
Grifols Launches a New Testing Service for Patients Treated with Daratumumab
May 30, 2018
Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for the Treatment of Multiple Myeloma
May 16, 2018
Janssen to Present New Data in Urothelial, Hematologic and Prostate Cancers at ASCO 2018, Including Best of ASCO Selections
May 07, 2018
Janssen Announces DARZALEX® (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible
Mar 26, 2018
Genmab A/S webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference